Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE:NVO) between November 2, 2022 and December 19, 2024, both dates inclusive (the "Class ...

Novo Nordisk is providing direct-to-patient delivery of Wegovy (semaglutide) through the NovoCare Pharmacy program.

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

"We are currently engaging with market participants," a spokesperson for South Africa's Competition Commission told Reuters, declining to provide details. USAID cuts put tuberculosis response in peril ...

The last few years have been tough for the insulin market, with recent policies and high-level pressure forcing companies to ...

This growth comes on the back of a steady market performance from 2017 to 2022, where the injection pen sector achieved a ...

California dedicated $100 to manufacturing insulin for diabetic residents. That effort is taking longer than Gov. Gavin ...

During a hearing, representatives for the Newsom administration said they could not provide a timeline for when ...

We came across a bullish thesis on Novo Nordisk A/S (NYSE ... Eli Lilly which is available at ~79x its trailing EPS. The worst-case scenario would imply flat sales for 2026-2030 with zero sales ...